Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program

Authors: Shu-Chen Kuo, Shan-Chwen Chang, Hui-Ying Wang, Jui-Fen Lai, Pei-Chen Chen, Yih-Ru Shiau, I-Wen Huang, Tsai-Ling Yang Lauderdale, TSAR Hospitals

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Acinetobacter baumannii complex (ABC) has emerged as an important pathogen causing a variety of infections. Longitudinal multicenter surveillance data on ABC from different sources in Taiwan have not been published. Using data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) conducted biennially, we investigated the secular change in resistance of 1640 ABC from 2002 to 2010 (TSAR period III to VII) to different antimicrobial agents and identified factors associated with imipenem-resistant and extensively drug-resistant ABC (IRABC and XDRABC).

Methods

Isolates were collected by TSAR from the same 26 hospitals located in all 4 regions of Taiwan. Minimum inhibitory concentrations (MIC) were determined by reference broth microdilution method. Isolates nonsusceptible to all tested aminoglycosides, fluoroquinolones, β-lactam, β-lactam/β-lactam inhibitors, and carbapenems were defined as extensively drug-resistant (XDR). Multivariate logistic regression analysis was performed to assess the relationship between predictor variables among patients with resistant ABC and patients with non-resistant ABC.

Results

The prevalence of IRABC increased from 3.4% in 2002 to 58.7% in 2010 (P < 0.001; odds ratio [OR], 2.138; 95% confidence interval [CI], 1.947 to 2.347) and that of XDRABC increased from 1.3% in 2002 to 41.0% in 2010 (P < 0.001; OR, 1.970; 95% CI, 1.773-2.189). The rates of non-susceptibility to other antimicrobial agents remained high (>55%) over the years with some fluctuations before and after TSAR V (2006) on some agents. Multivariate analysis revealed that recovery from elderly patients, origins other than blood, from ICU settings, or geographic regions are independent factors associated with IRABC and XDRABC. Although the prevalence of XDRABC increased in all four regions of Taiwan over the years, central Taiwan had higher prevalence of XDRABC starting in 2008. Susceptibility to polymyxin remained high (99.8%).

Conclusions

This longitudinal multicenter surveillance program revealed significant increase and nationwide emergence of IRABC and XDRABC in Taiwan over the years. This study also identified factors associated with IRABC and XDRABC to help guide empirical therapy and at-risk groups requiring more intense interventional infection control measures with focused surveillance efforts.
Appendix
Available only for authorised users
Literature
1.
go back to reference Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008, 21: 538-582. 10.1128/CMR.00058-07.CrossRefPubMedPubMedCentral Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008, 21: 538-582. 10.1128/CMR.00058-07.CrossRefPubMedPubMedCentral
2.
go back to reference Dijkshoorn L, Nemec A, Seifert H: An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007, 5: 939-951. 10.1038/nrmicro1789.CrossRefPubMed Dijkshoorn L, Nemec A, Seifert H: An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007, 5: 939-951. 10.1038/nrmicro1789.CrossRefPubMed
3.
go back to reference Neonakis IK, Spandidos DA, Petinaki E: Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011, 37: 102-109. 10.1016/j.ijantimicag.2010.10.014.CrossRefPubMed Neonakis IK, Spandidos DA, Petinaki E: Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011, 37: 102-109. 10.1016/j.ijantimicag.2010.10.014.CrossRefPubMed
4.
go back to reference Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007, 51: 3471-3484. 10.1128/AAC.01464-06.CrossRefPubMedPubMedCentral Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007, 51: 3471-3484. 10.1128/AAC.01464-06.CrossRefPubMedPubMedCentral
5.
go back to reference Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007, 59: 525-530. 10.1093/jac/dkl499.CrossRefPubMed Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007, 59: 525-530. 10.1093/jac/dkl499.CrossRefPubMed
6.
go back to reference Sunenshine RH, Wright M-O, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, et al: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007, 13: 97-103. 10.3201/eid1301.060716.CrossRefPubMedPubMedCentral Sunenshine RH, Wright M-O, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, et al: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007, 13: 97-103. 10.3201/eid1301.060716.CrossRefPubMedPubMedCentral
7.
go back to reference Peleg AY, Paterson DL: Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J. 2006, 36: 479-482. 10.1111/j.1445-5994.2006.01130.x.CrossRefPubMed Peleg AY, Paterson DL: Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J. 2006, 36: 479-482. 10.1111/j.1445-5994.2006.01130.x.CrossRefPubMed
8.
go back to reference Turner PJ: Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis. 2008, 60: 185-192. 10.1016/j.diagmicrobio.2007.09.006.CrossRefPubMed Turner PJ: Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis. 2008, 60: 185-192. 10.1016/j.diagmicrobio.2007.09.006.CrossRefPubMed
9.
go back to reference Gales AC, Jones RN, Sader HS: Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother. 2011, 66: 2070-2074. 10.1093/jac/dkr239.CrossRefPubMed Gales AC, Jones RN, Sader HS: Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother. 2011, 66: 2070-2074. 10.1093/jac/dkr239.CrossRefPubMed
10.
go back to reference Jean S-S, Hsueh P-R: High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011, 37: 291-295. 10.1016/j.ijantimicag.2011.01.009.CrossRefPubMed Jean S-S, Hsueh P-R: High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011, 37: 291-295. 10.1016/j.ijantimicag.2011.01.009.CrossRefPubMed
11.
go back to reference Lauderdale TL, Clifford McDonald L, Shiau YR, Chen PC, Wang HY, Lai JF, Ho M: The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis. 2004, 48: 211-219. 10.1016/j.diagmicrobio.2003.10.005.CrossRefPubMed Lauderdale TL, Clifford McDonald L, Shiau YR, Chen PC, Wang HY, Lai JF, Ho M: The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis. 2004, 48: 211-219. 10.1016/j.diagmicrobio.2003.10.005.CrossRefPubMed
12.
go back to reference White AR, Surveillance BWPoR: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. J Antimicrob Chemother. 2008, 62 (2): ii3-ii14. 10.1093/jac/dkn348.PubMed White AR, Surveillance BWPoR: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. J Antimicrob Chemother. 2008, 62 (2): ii3-ii14. 10.1093/jac/dkn348.PubMed
13.
go back to reference Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY: Emergence and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect. 2011, 44: 157-165. 10.1016/j.jmii.2011.03.001.CrossRefPubMed Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY: Emergence and spread of multi-drug resistant organisms: think globally and act locally. J Microbiol Immunol Infect. 2011, 44: 157-165. 10.1016/j.jmii.2011.03.001.CrossRefPubMed
14.
go back to reference Jean S-S, Hsueh P-R, Lee W-S, Chang H-T, Chou M-Y, Chen I-S, Wang J-H, Lin C-F, Shyr J-M, Ko W-C, et al: Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents. 2009, 33: 266-271. 10.1016/j.ijantimicag.2008.08.026.CrossRefPubMed Jean S-S, Hsueh P-R, Lee W-S, Chang H-T, Chou M-Y, Chen I-S, Wang J-H, Lin C-F, Shyr J-M, Ko W-C, et al: Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents. 2009, 33: 266-271. 10.1016/j.ijantimicag.2008.08.026.CrossRefPubMed
15.
go back to reference Ho M, McDonald LC, Lauderdale TL, Yeh LL, Chen PC, Shiau YR: Surveillance of antibiotic resistance in Taiwan, 1998. J Microbiol Immunol Infect. 1999, 32: 239-249.PubMed Ho M, McDonald LC, Lauderdale TL, Yeh LL, Chen PC, Shiau YR: Surveillance of antibiotic resistance in Taiwan, 1998. J Microbiol Immunol Infect. 1999, 32: 239-249.PubMed
16.
go back to reference Chen FJ, Huang IW, Wang CH, Chen PC, Wang HY, Lai JF, Shiau YR, Lauderdale TL: mecA-positive Staphylococcus aureus with low-level oxacillin MIC in Taiwan. J Clin Microbiol. 2012, 50: 1679-1683. 10.1128/JCM.06711-11.CrossRefPubMedPubMedCentral Chen FJ, Huang IW, Wang CH, Chen PC, Wang HY, Lai JF, Shiau YR, Lauderdale TL: mecA-positive Staphylococcus aureus with low-level oxacillin MIC in Taiwan. J Clin Microbiol. 2012, 50: 1679-1683. 10.1128/JCM.06711-11.CrossRefPubMedPubMedCentral
17.
go back to reference Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC: A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect. 2012, 45: 120-126. 10.1016/j.jmii.2011.09.028.CrossRefPubMed Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC: A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect. 2012, 45: 120-126. 10.1016/j.jmii.2011.09.028.CrossRefPubMed
18.
go back to reference Schreckenberger PC, von Graevenitz A: Acinetobacter, Achromobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative rods. p. 539–560. Manual of Clinical Microbiology. Edited by: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. 1999, American Society for Microbiology, Washington, D.C., 7 Schreckenberger PC, von Graevenitz A: Acinetobacter, Achromobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative rods. p. 539–560. Manual of Clinical Microbiology. Edited by: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. 1999, American Society for Microbiology, Washington, D.C., 7
19.
go back to reference Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement. 2011, CLSI document M100-S21, CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement. 2011, CLSI document M100-S21, CLSI, Wayne, PA
20.
go back to reference Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012, 18: 268-281. 10.1111/j.1469-0691.2011.03570.x.CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012, 18: 268-281. 10.1111/j.1469-0691.2011.03570.x.CrossRefPubMed
21.
go back to reference Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL: In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother. 2011, 55: 436-438. 10.1128/AAC.00850-10.CrossRefPubMed Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL: In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother. 2011, 55: 436-438. 10.1128/AAC.00850-10.CrossRefPubMed
22.
go back to reference Stelling JM, O'Brien TF: Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis. 1997, 24 (Suppl 1): S157-168.CrossRefPubMed Stelling JM, O'Brien TF: Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis. 1997, 24 (Suppl 1): S157-168.CrossRefPubMed
23.
go back to reference Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y: Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009, 302: 627-637. 10.1001/jama.2009.1144.CrossRefPubMedPubMedCentral Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y: Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009, 302: 627-637. 10.1001/jama.2009.1144.CrossRefPubMedPubMedCentral
24.
go back to reference Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ: Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007, 60: 1018-1029. 10.1093/jac/dkm310.CrossRefPubMed Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ: Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007, 60: 1018-1029. 10.1093/jac/dkm310.CrossRefPubMed
25.
go back to reference Falagas ME, Kopterides P: Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006, 64: 7-15. 10.1016/j.jhin.2006.04.015.CrossRefPubMed Falagas ME, Kopterides P: Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006, 64: 7-15. 10.1016/j.jhin.2006.04.015.CrossRefPubMed
26.
go back to reference Lin MF, Kuo HY, Yeh HW, Yang CM, Sung CH, Tu CC, Huang ML, Liou ML: Emergence and dissemination of bla(OXA-23)-carrying imipenem-resistant Acinetobacter sp. in a regional hospital in Taiwan. J Microbiol Immunol Infect. 2011, 44: 39-44. 10.1016/j.jmii.2011.01.008.CrossRefPubMed Lin MF, Kuo HY, Yeh HW, Yang CM, Sung CH, Tu CC, Huang ML, Liou ML: Emergence and dissemination of bla(OXA-23)-carrying imipenem-resistant Acinetobacter sp. in a regional hospital in Taiwan. J Microbiol Immunol Infect. 2011, 44: 39-44. 10.1016/j.jmii.2011.01.008.CrossRefPubMed
27.
go back to reference Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N: Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother. 2009, 63: 641-647. 10.1093/jac/dkn553.CrossRefPubMed Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N: Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother. 2009, 63: 641-647. 10.1093/jac/dkn553.CrossRefPubMed
28.
go back to reference Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC: Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One. 2012, 7: e37788-10.1371/journal.pone.0037788.CrossRefPubMedPubMedCentral Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC: Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One. 2012, 7: e37788-10.1371/journal.pone.0037788.CrossRefPubMedPubMedCentral
29.
go back to reference Smani Y, Lopez-Rojas R, Dominguez-Herrera J, Docobo-Perez F, Marti S, Vila J, Pachon J: In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2012, 18: E1-E4. 10.1111/j.1469-0691.2011.03695.x.CrossRefPubMed Smani Y, Lopez-Rojas R, Dominguez-Herrera J, Docobo-Perez F, Marti S, Vila J, Pachon J: In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2012, 18: E1-E4. 10.1111/j.1469-0691.2011.03695.x.CrossRefPubMed
30.
go back to reference Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H: Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol. 2012, Feb 02 [Epub ahead of print] Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H: Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol. 2012, Feb 02 [Epub ahead of print]
31.
go back to reference Ko KS, Suh JY, Kwon KT, Jung S-I, Park K-H, Kang CI, Chung DR, Peck KR, Song J-H: High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007, 60: 1163-1167. 10.1093/jac/dkm305.CrossRefPubMed Ko KS, Suh JY, Kwon KT, Jung S-I, Park K-H, Kang CI, Chung DR, Peck KR, Song J-H: High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007, 60: 1163-1167. 10.1093/jac/dkm305.CrossRefPubMed
32.
go back to reference Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN: The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect. 2010, 60: 440-451. 10.1016/j.jinf.2010.03.024.CrossRefPubMed Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN: The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect. 2010, 60: 440-451. 10.1016/j.jinf.2010.03.024.CrossRefPubMed
Metadata
Title
Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program
Authors
Shu-Chen Kuo
Shan-Chwen Chang
Hui-Ying Wang
Jui-Fen Lai
Pei-Chen Chen
Yih-Ru Shiau
I-Wen Huang
Tsai-Ling Yang Lauderdale
TSAR Hospitals
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-200

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.